Cogent Biosciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cogent Biosciences Inc's ROI in the second quarter of 2026?
Cogent Biosciences Inc recorded a cumulative net loss of $-377 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -49.28%.

Within the Healthcare sector 97 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2218 to 3739.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	190.47 %	87.26 %	17.85 %	-24.3 %	-26.05 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	979	845	874	364	216
Return On Investment (TTM)	-49.28 %	-61.65 %	-77.94 %	-108.35 %	-107.81 %
COGT's Overall Ranking	# 3739	# 2218	# 2631	# 3480	# 3650
Seq. Investment Change TTM	33.19 %	36.17 %	55.35 %	3.1 %	-14.14 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-377	-354	-329	-294	-284

COGT Company Profile >> Back to COGT Roi Comparisons >> See Annual COGT Return On Investment

Return On Investment COGT's Ranking
Within:	No.
Industry	# 28
Sector	# 98
Overall	# 3739

Return On Investment Statistics
High	Average	Low
-3.61 %	-69.6 %	-174.82 %
(Mar 31 2018)		(Dec 31 2020)

News about Cogent Biosciences Inc Return on Investment ROI

Cogent Biosciences: Navigating Financial Turbulence While Pioneering Breakthroughs in Cancer Therapy

January 13, 2025

As the biotech sector grapples with economic headwinds, Cogent Biosciences Inc. stands at a pivotal juncture in its mission to advance targeted therapies for cancer. Despite its cumulative net loss of $242 million over the past year, the company is forging ahead with ambitious milestones for its lead drug, Bezuclastinib, and its new portfolio of selective therapeutics. In a recent announcement, Cogent disclosed it plans to report top-line results from the registration-directed SUMMIT trial in patients with Non-Advanced Sys-temic Mastocytosis (NonAdvSM) by July 2025. This trial is part of the company’s broader strategy to establish its foothold in a competitive market while addressing the unmet needs of patients afflicted by rare conditions.One significant achievement for Cogent has been the successful completion of patient enrollment in its Phase 3 PEAK trial for Gastrointestinal Stromal Tumors (GIST). Surpassing targets, 413 patients are now participating—an impressive feat that underscores the company’s potential to deliver meaningful outcomes in a disease characterized by complex treatment challenges. Moreover, the trial’s advancement after the interim futility analysis represents a critical validation of Cogent’s innovative approach to addressing GIST, a rare digestive tract cancer.

Financial Statements
Cogent Biosciences Inc's II. Quarter Investments	$ 979 Millions	COGT's Balance sheet
Cogent Biosciences Inc's II. Quarter Income	$ -96 Millions	Quarterly COGT's Income Statement
COGT's Income by Division		See COGT's Income by Division

COGT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	874	272	275	274	215
Y / Y Investment Growth	220.97 %	-1.12 %	0.48 %	27.41 %	-9.59 %
Net Income in Millions	-329	-256	-192	-140	-72
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-37.65 %	-94 %	-69.9 %	-51.19 %	-33.61 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
COGT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for COGT's Competitors
Subscribers only: Roi for Cogent Biosciences Inc's Suppliers
Subscribers only: Return On Investment for COGT's Customers

Other Ratios
COGT's Roa	COGT's Inventory Turnover Ratio	COGT's Growth Rates	COGT's Dividend Statistics
	COGT's Profitability Ratios	COGT's Asset Turnover Ratio	COGT's Dividend Growth
COGT's Roe	COGT's Valuation Ratios	COGT's Financial Strength Ratios	COGT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:33:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.